II. Mechanism
- Cellular channel effects
- Effects slow Calcium channel activity (blocks voltage-gated L-type Calcium channels)
- Agents block both Calcium and Sodium inflow into cells during smooth muscle Action Potential phase
- Channels are present in cardiac and vascular Smooth Muscle
- Calcium Channel Blocker effects
- Myocardial relaxation (Non-Dihydropyridines primarily)
- Vascular Smooth Muscle relaxation
- Pancreatic B-islet cell inhibition
- Inhibits gastrointestinal Smooth Muscle propulsion (resulting in Constipation)
III. Types
-
Dihydropyridine (e.g. Nifedipine, Amlodipine)
- Primary effects are on peripheral vasculature, resulting in vasodilation (with possible reflex increased Heart Rate)
- Amlodipine (Norvasc) is most commonly used and typically for Hypertension
- Nicardipine and Clevidipine are most commonly used in Hypertensive Emergency
- Non-Dihydropiridine (e.g. Verapamil, Diltiazem)
- Effect both peripheral vasculature and cardiac tissue, with a decrease in Heart Rate and Blood Pressure
- Diltiazem is most commonly used and typically used for Atrial Fibrillation Rate Control
IV. Adverse Effects: Myocardial Infarction
- Short Acting Calcium Channel Blockers
- Findings
- Myocardial Infarction Risk: 60% over Diuretics
- Higher dose confers >3x risk of lower dose
- References
- Findings
- Long acting Calcium Channel Blockers
- No increased cardiovascular disease risk
- Reference
V. Adverse Effects: Bleeding risk
- Findings
- Higher Incidence of GI Hemorrhage in elderly
- Associated with Platelet aggregation inhibition
- Avoid in older patients if:
- Peptic Ulcer Disease
- Concurrent Aspirin use
- Perioperative
- References
VI. Adverse Effects: General
- Hypotension
- Flushing
- Nasal congestion
- Tachycardia
- Dizziness
- Nausea
- Nervousness
- Bowel changes
- Gingival Hyperplasia
-
Eczematous Dermatitis (or other skin reactions)
- Occurs in up to 1% of patients on Calcium Channel Blockers
- Delayed onset at 3 months after starting Calcium Channel Blockers
- Joly (2007) J Invest Dermatol 127(12):2766-71 [PubMed]
VII. References
- (2022) Presc Lett 29(11): 64-5
- Yen (2015) Crit Dec Emerg Med 29(10): 18-23